Vanta Announces Strategic Agreement to Support U.S. Peptide Market Entry Through FDA-Registered Supply Chain and Compliant Payment Processing Infrastructure; Advancing U.S.-Focused Longevity and Consumer Health Sciences Platform

Executive Summary of Recent Developments

• Vanta Holdings Inc. announced a strategic operating agreement on May 28, 2026, to enter the U.S. peptide therapeutics market via FDA-registered supply chains and telehealth infrastructure.
• New subsidiaries established: Vanta Peptide Labs Inc. (British Columbia) and Vanta Amino Sciences Incorporated (Wyoming).
• Initial capital requirement for launch estimated at CAD$850,000 to cover inventory, fulfillment, telehealth onboarding, and regulatory compliance.
• Strategic Partner Compensation includes US$10,000/month management fees for the first six months, rising to US$20,000/month thereafter, plus 25% quarterly profit participation.
• Fees commence August 1, 2026, or upon closing a private placement ≥CAD$1,000,000 or receipt of first commercial purchase order.

Evaluation of Strategic Shift

• The move into peptide therapeutics targets a projected US$160.3 billion market by 2030, representing a significant sector pivot from existing nutraceutical/hydration portfolios.
• However, the capital requirement (CAD$850,000) exceeds the most recent financing proceeds ($385,000), creating an immediate funding gap of approximately $465,000 plus ongoing monthly operating fees ($10k-$20k).
• No strategic investors with significant track records (e.g., Sprott, Lundin, Lassonde) are identified in this agreement; the partner is described as "arm's length."
• The news does not confirm new capital raised to fund this specific initiative, implying a follow-on financing announcement is likely imminent.

Business Model

• Vanta Holdings operates in the consumer health and longevity sector, previously focused on nutraceuticals and hydration products.
• The flagship initiative is now the U.S.-focused peptide therapy platform leveraging telehealth infrastructure and FDA-registered compounding pharmacies (503A/503B).